Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases

E. Cortesi, L. Capussotti, P. Di Tora, E. Mannella, V. Casaldi, D. Civalleri, G. B. Morandi, P. P. Da Pian, A. Padovani, A. Callopoli, D. Giannarelli, M. Cosimelli

Research output: Contribution to journal › Article

9 Citations (Scopus)

Abstract

A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolus vs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 mg/m2/day, 1→5, bolus vs. continuous infusion) and systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day, 1→5; escalating doses, respectively, at cycles I, II, III, and VI). To avoid neurotoxicity a maximum of six cycles was administered. RESULTS: Preliminary results for the 78 evaluable patients are similar to those of the previous study: response rate 46 percent and at a median follow-up of 16.5 months, the overall survival was 16.5 months, with 45 percent of the patients who received more than 3 cycles alive at 3 years. Toxicity, evaluable in 99 patients, showed a decreased incidence of neurotoxicity and a tolerable gastrointestinal and hematologic toxicity, lower in the cisplatin continuous infusion arm. CONCLUSION: This study clearly shows that cisplatin intrahepatic arterial infusion is able to provide a good palliative effect with a tolerable toxicity.

Original languageEnglish
JournalDiseases of the Colon and Rectum
Volume37
Issue number2 Supplement
DOIs
Publication statusPublished - Feb 1994

Fingerprint

Fluorouracil
Cisplatin
Neoplasm Metastasis
Drug Therapy
Liver
Intravenous Infusions
Nervous System
Appointments and Schedules
Survival Rate
Survival
Incidence

Keywords

  • Chemotherapy
  • Cisplatin
  • Colorectal liver metastases
  • Continuous infusion
  • Hepatic arterial infusion

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases. / Cortesi, E.; Capussotti, L.; Di Tora, P.; Mannella, E.; Casaldi, V.; Civalleri, D.; Morandi, G. B.; Da Pian, P. P.; Padovani, A.; Callopoli, A.; Giannarelli, D.; Cosimelli, M.

In: Diseases of the Colon and Rectum, Vol. 37, No. 2 Supplement, 02.1994.

Research output: Contribution to journal › Article

Cortesi, E, Capussotti, L, Di Tora, P, Mannella, E, Casaldi, V, Civalleri, D, Morandi, GB, Da Pian, PP, Padovani, A, Callopoli, A, Giannarelli, D & Cosimelli, M 1994, 'Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases', Diseases of the Colon and Rectum, vol. 37, no. 2 Supplement. https://doi.org/10.1007/BF02048447
Cortesi E, Capussotti L, Di Tora P, Mannella E, Casaldi V, Civalleri D et al. Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases. Diseases of the Colon and Rectum. 1994 Feb;37(2 Supplement). https://doi.org/10.1007/BF02048447
Cortesi, E. ; Capussotti, L. ; Di Tora, P. ; Mannella, E. ; Casaldi, V. ; Civalleri, D. ; Morandi, G. B. ; Da Pian, P. P. ; Padovani, A. ; Callopoli, A. ; Giannarelli, D. ; Cosimelli, M. / Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases. In: Diseases of the Colon and Rectum. 1994 ; Vol. 37, No. 2 Supplement.
@article{354259750f3041babff26893045f3d25,
title = "Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases",
abstract = "A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolus vs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 mg/m2/day, 1→5, bolus vs. continuous infusion) and systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day, 1→5; escalating doses, respectively, at cycles I, II, III, and VI). To avoid neurotoxicity a maximum of six cycles was administered. RESULTS: Preliminary results for the 78 evaluable patients are similar to those of the previous study: response rate 46 percent and at a median follow-up of 16.5 months, the overall survival was 16.5 months, with 45 percent of the patients who received more than 3 cycles alive at 3 years. Toxicity, evaluable in 99 patients, showed a decreased incidence of neurotoxicity and a tolerable gastrointestinal and hematologic toxicity, lower in the cisplatin continuous infusion arm. CONCLUSION: This study clearly shows that cisplatin intrahepatic arterial infusion is able to provide a good palliative effect with a tolerable toxicity.",
keywords = "Chemotherapy, Cisplatin, Colorectal liver metastases, Continuous infusion, Hepatic arterial infusion",
author = "E. Cortesi and L. Capussotti and {Di Tora}, P. and E. Mannella and V. Casaldi and D. Civalleri and Morandi, {G. B.} and {Da Pian}, {P. P.} and A. Padovani and A. Callopoli and D. Giannarelli and M. Cosimelli",
year = "1994",
month = "2",
doi = "10.1007/BF02048447",
language = "English",
volume = "37",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "2 Supplement",

}

TY - JOUR

T1 - Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases

AU - Cortesi, E.

AU - Capussotti, L.

AU - Di Tora, P.

AU - Mannella, E.

AU - Casaldi, V.

AU - Civalleri, D.

AU - Morandi, G. B.

AU - Da Pian, P. P.

AU - Padovani, A.

AU - Callopoli, A.

AU - Giannarelli, D.

AU - Cosimelli, M.

PY - 1994/2

Y1 - 1994/2

N2 - A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolus vs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 mg/m2/day, 1→5, bolus vs. continuous infusion) and systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day, 1→5; escalating doses, respectively, at cycles I, II, III, and VI). To avoid neurotoxicity a maximum of six cycles was administered. RESULTS: Preliminary results for the 78 evaluable patients are similar to those of the previous study: response rate 46 percent and at a median follow-up of 16.5 months, the overall survival was 16.5 months, with 45 percent of the patients who received more than 3 cycles alive at 3 years. Toxicity, evaluable in 99 patients, showed a decreased incidence of neurotoxicity and a tolerable gastrointestinal and hematologic toxicity, lower in the cisplatin continuous infusion arm. CONCLUSION: This study clearly shows that cisplatin intrahepatic arterial infusion is able to provide a good palliative effect with a tolerable toxicity.

AB - A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolus vs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 mg/m2/day, 1→5, bolus vs. continuous infusion) and systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day, 1→5; escalating doses, respectively, at cycles I, II, III, and VI). To avoid neurotoxicity a maximum of six cycles was administered. RESULTS: Preliminary results for the 78 evaluable patients are similar to those of the previous study: response rate 46 percent and at a median follow-up of 16.5 months, the overall survival was 16.5 months, with 45 percent of the patients who received more than 3 cycles alive at 3 years. Toxicity, evaluable in 99 patients, showed a decreased incidence of neurotoxicity and a tolerable gastrointestinal and hematologic toxicity, lower in the cisplatin continuous infusion arm. CONCLUSION: This study clearly shows that cisplatin intrahepatic arterial infusion is able to provide a good palliative effect with a tolerable toxicity.

KW - Chemotherapy

KW - Cisplatin

KW - Colorectal liver metastases

KW - Continuous infusion

KW - Hepatic arterial infusion

UR - http://www.scopus.com/inward/record.url?scp=0028354253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028354253&partnerID=8YFLogxK

U2 - 10.1007/BF02048447

DO - 10.1007/BF02048447

M3 - Article

VL - 37

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 2 Supplement

ER -

Access to Document